Soligenix, Inc. (SNGX)
$
1.25
-0.06 (-4.80%)
Key metrics
Financial statements
Free cash flow per share
-2.2486
Market cap
13.8 Million
Price to sales ratio
0
Debt to equity
0.0507
Current ratio
3.1797
Income quality
0.9394
Average inventory
0
ROE
-2.6710
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases in the United States. The company reported a net loss of -$8,266,576.00 indicating challenges in its operations. In terms of core operations, the gross profit stands at -$119,371.00 which highlights the company's profitability from its main activities. The cost of revenue for the company is $119,371.00 showcasing its production and operational expenses associated with the development and commercialization of its products. Furthermore, the net income ratio is 0.00 reflecting the company's profitability margin and operational efficiency. Additionally, the net total of other income and expenses is $763,807.00 which provides insight into the organization’s non-core financial activities. Soligenix operates within two segments, Specialized BioTherapeutics and Public Health Solutions, developing innovative therapies such as SGX301 (HyBryte) for cutaneous T-cell lymphoma and SGX942 for inflammatory diseases, among others. Soligenix's stock is affordable at $2.69 making it an attractive option for budget-conscious investors. However, it has a low average trading volume of 308,891.00 indicating lower market activity, which could affect liquidity for potential investors. With a market capitalization of $12,607,663.00 the company is classified as a small-cap player, which often entails a different risk and growth profile compared to larger corporations. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its innovative therapies and public health solutions. Additionally, it belongs to the Healthcare sector, driving innovation and growth in the biopharmaceutical space, which plays a vital role in addressing unmet medical needs and advancing healthcare solutions.
Is Soligenix, Inc. (SNGX) a good investment?
Investing in Soligenix, Inc. (SNGX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Soligenix, Inc. (SNGX)'s stock forecast?
Analysts predict Soligenix, Inc. stock to fluctuate between $1.09 (low) and $6.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Soligenix, Inc.'s market capitalization?
As of 2026-01-30, Soligenix, Inc.'s market cap is $12,607,663, based on 10,086,130 outstanding shares.
How does Soligenix, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Soligenix, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Soligenix, Inc. (SNGX) stock?
To buy Soligenix, Inc. (SNGX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SNGX. Place an order (Market, Limit, etc.).
What is the best time to invest in Soligenix, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Soligenix, Inc. stock ever split?
Soligenix, Inc.'s last stock split was 1:16 on 2024-06-06.
How did Soligenix, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$4.98 | Growth: -60.66%.
Where can I find Soligenix, Inc.'s investor relations reports?
Visit https://www.soligenix.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Soligenix, Inc.?
You can explore historical data from here
What is the all-time high and low for Soligenix, Inc. stock?
All-time high: $294.91 (2021-09-09) | All-time low: $1.09 (2025-07-08).
What are the key trends affecting Soligenix, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J. , Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease have been published in Rheumatology (Oxford), in an article entitled "Results from a Pilot Study of Dusquetide for the Treatment of Aphthous Ulcers Associated with Behçet Syndrome".
benzinga.com
Soligenix, Inc. (NASDAQ: SNGX) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.
prnewswire.com
Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON, N.J. , Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.
globenewswire.com
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
prnewswire.com
50 of 80 patients enrolled in FLASH 2 study Blinded Response Rate to Date Exceeds Trial Estimate PRINCETON, N.J. , Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has completed the planned enrollment of 50 patients necessary for the interim analysis in its 80 patient confirmatory Phase 3 double-blind, placebo-controlled study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL).
prnewswire.com
PRINCETON, N.J. , Nov. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2025.
prnewswire.com
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J. , Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the update of its United States (U.S.) Medical Advisory Board (MAB) for cutaneous T-cell lymphoma (CTCL) to provide medical/clinical strategic guidance to the Company as it advances the Phase 3 clinical development of HyBryte™ (synthetic hypericin) for the treatment of CTCL, a rare class of non-Hodgkin's lymphoma (NHL).
prnewswire.com
FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J. , Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its first Data Monitoring Committee (DMC) meeting for its confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) has concluded that there are no safety concerns with the ongoing Phase 3 study and that HyBryte™ has an acceptable safety profile that remains consistent with the safety data from all prior clinical studies.
prnewswire.com
In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J. , Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the expansion of its European Medical Advisory Board (MAB) to provide additional medical/clinical strategic guidance to the Company as it advances its confirmatory Phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL) patients with early-stage disease.
prnewswire.com
PRINCETON, N.J. , Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its "reasonable best efforts" public offering with existing and certain healthcare focused institutional investors for the purchase and sale of 5,555,560 shares of common stock of the Company (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share and accompanying warrant (the "Offering").
See all news
